Osteolectin Promotes Odontoblastic Differentiation in Human Dental Pulp Cells.


Journal

Journal of endodontics
ISSN: 1878-3554
Titre abrégé: J Endod
Pays: United States
ID NLM: 7511484

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 27 06 2023
revised: 08 09 2023
accepted: 20 09 2023
medline: 24 11 2023
pubmed: 30 9 2023
entrez: 29 9 2023
Statut: ppublish

Résumé

Osteolectin is a secreted glycoprotein of the C-type lectin domain superfamily, expressed in bone tissues and is reported as a novel osteogenic factor that promotes bone regeneration. However, the effect of osteolectin on human dental pulp cells (hDPCs) has not been reported. Therefore, we aimed to investigate the odontoblastic differentiation of osteolectin in hDPCs and further attempt to reveal its underlying mechanism. Cytotoxicity assays were used to detect the cytotoxicity of osteolectin. The odontoblastic differentiation of hDPCs and its underlying mechanisms were measured by the alkaline phosphatase (ALP) activity, mineralized spots formation, and the gene and protein expression of odontoblastic differentiation through ALP staining, Alizarin red S staining, quantitative real-time polymerase chain reaction, and Western blot analysis, respectively. WST-1 assay showed osteolectin at concentrations below 300 ng/ml was noncytotoxic and safe for hDPCs. The following experiment demonstrated that osteolectin could increase ALP activity, accelerate the mineralization process, and up-regulate the odontogenic differentiation markers in both gene and protein levels (P < .05). Osteolectin stimulated the phosphorylation of ERK, JNK, and Protein kinase B (AKT) in hDPCs. Extracellular signal-regulated kinase (ERK), Jun N-terminal kinase (JNK), and AKT inhibitors decreased ALP activity and mineralization capacity and suppressed the expression of dentin sialophosphoprotein and dentin matrix protein-1. Osteolectin can promote odontoblastic differentiation of hDPCs, and the whole process may stimulate ERK, JNK, and AKT signaling pathways by increasing p-ERK, p-JNK, and p-AKT signals.

Identifiants

pubmed: 37774945
pii: S0099-2399(23)00611-8
doi: 10.1016/j.joen.2023.09.010
pii:
doi:

Substances chimiques

Proto-Oncogene Proteins c-akt EC 2.7.11.1
Extracellular Matrix Proteins 0
Alkaline Phosphatase EC 3.1.3.1
Phosphoproteins 0

Types de publication

Journal Article

Langues

eng

Pagination

1660-1667

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Manfei Qiu (M)

Department of Conservative Dentistry, School of Dentistry, Dental Science Research Institute, Chonnam National University, Gwangju, Republic of Korea.

Kkot-Byeol Bae (KB)

Department of Conservative Dentistry, School of Dentistry, Dental Science Research Institute, Chonnam National University, Gwangju, Republic of Korea.

Guo Liu (G)

Department of Conservative Dentistry, School of Dentistry, Dental Science Research Institute, Chonnam National University, Gwangju, Republic of Korea; Department of Endodontics, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, China.

Ji-Hyun Jang (JH)

Department of Conservative Dentistry, School of Dentistry, Kyung Hee University, Seoul, Republic of Korea.

Jeong-Tae Koh (JT)

Department of Pharmacology and Dental Therapeutics, School of Dentistry, Dental Science Research, Institute, Chonnam National University, Gwangju, Republic of Korea; Research Center for Biomineralization Disorders, Chonnam National University, Gwangju, Republic of Korea.

Yun-Chan Hwang (YC)

Department of Conservative Dentistry, School of Dentistry, Dental Science Research Institute, Chonnam National University, Gwangju, Republic of Korea.

Bin-Na Lee (BN)

Department of Conservative Dentistry, School of Dentistry, Dental Science Research Institute, Chonnam National University, Gwangju, Republic of Korea. Electronic address: bnlee13@jnu.ac.kr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH